荷兰和丹麦队列中巨细胞动脉炎与风湿性多肌痛患者的代谢特征及糖皮质激素诱导的合并症
在荷兰GPS队列中分析未治疗巨细胞动脉炎(GCA,n=50)和风湿性多肌痛(PMR,n=42)患者的代谢特征及合并症,并与Lifelines人群(n=91)比较,同时纳入丹麦Aarhus队列(GCA n=52,PMR n=25)验证。未治疗GCA患者糖化血红蛋白趋于更高而高密度脂蛋白、低密度脂蛋白和胆固醇更低;基线合并症不能预测长期糖皮质激素需求;GCA患者启动糖皮质激素后糖尿病、肥胖和白内障发生率增加。
要点
- 未治疗GCA患者糖化血红蛋白趋于更高,高密度脂蛋白、低密度脂蛋白和胆固醇低于Lifelines人群。
- 基线合并症存在与否不能预测长期糖皮质激素需求。
- GCA患者启动糖皮质激素治疗后糖尿病、肥胖和白内障发生率增加。
核心结论
- GCA和PMR队列数据提示未治疗GCA患者存在代谢失调,而PMR患者未见此现象。
- 糖皮质激素治疗导致合并症增加和代谢谱更不健康,强调这些脆弱患者需要泼尼松节约型靶向治疗。
研究设计与样本
- 在荷兰GCA/PMR/SENEX(GPS)队列中分析未治疗GCA(n=50)和PMR(n=42)患者的代谢特征及合并症患病率,并与基于人群的Lifelines队列(n=91)比较。
- 纳入丹麦Aarhus队列GCA(n=52)和PMR(n=25)患者数据以比较GPS队列的发现。
- GPS队列记录实验室测量、合并症和糖皮质激素使用长达5年。
主要发现
- 未治疗GCA患者糖化血红蛋白水平趋于更高,而高密度脂蛋白、低密度脂蛋白和胆固醇水平低于Lifelines人群。
- Aarhus队列数据与GPS队列所得发现一致。
- 基线时合并症的存在不能预测长期糖皮质激素需求。
- GCA患者启动糖皮质激素治疗后糖尿病、肥胖和白内障的发生率增加。
关键数值与推荐
- 分析的合并症包括2型糖尿病、高胆固醇血症、高血压、肥胖和白内障。
- GPS队列中GCA n=50、PMR n=42、Lifelines n=91;Aarhus队列中GCA n=52、PMR n=25。
- GPS队列中实验室测量、合并症和糖皮质激素使用记录长达5年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are age-associated inflammatory diseases that frequently overlap. Both diseases require long-term treatment with glucocorticoids (GCs), often associated with comorbidities. Previous population-based cohort studies reported that an unhealthier metabolic profile might prevent the development of GCA. Here, we report metabolic features before start of treatment and during treatment in patients with GCA and PMR. METHODS: In the Dutch GCA/PMR/SENEX (GPS) cohort, we analysed metabolic features and prevalence of comorbidities (type 2 diabetes, hypercholesterolaemia, hypertension, obesity and cataract) in treatment-naïve patients with GCA (n=50) and PMR (n=42), and compared those with the population-based Lifelines cohort (n=91). To compare our findings in the GPS cohort, we included data from patients with GCA (n=52) and PMR (n=25) from the Aarhus cohort. Laboratory measurements, comorbidities and GC use were recorded for up to 5 years in the GPS cohort. RESULTS: Glycated haemoglobin levels tended to be higher in treatment-naïve patients with GCA, whereas high-density lipoprotein, low-density lipoprotein and cholesterol levels were lower compared with the Lifelines population. Data from the Aarhus cohort were aligned with the findings obtained in the GPS cohort. Presence of comorbidities at baseline did not predict long-term GC requirement. The incidence of diabetes, obesity and cataract among patients with GCA increased upon initiation of GC treatment. CONCLUSION: Data from the GCA and PMR cohorts imply a metabolic dysregulation in treatment-naïve patients with GCA, but not in patients with PMR. Treatment with GCs led to the rise of comorbidities and an unhealthier metabolic profile, stressing the need for prednisone-sparing targeted treatment in these vulnerable patients.
引用
- Esen I, Arends S, Dalsgaard Nielsen B, et al. Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort. RMD Open. 2023. PMID: 36631159. doi:10.1136/rmdopen-2022-002640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。